Open AccessNovel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia
Author(s) -
Alexander Gavralidis,
Andrew M. Brunner
Publication year - 2020
Publication title -
current hematologic malignancy reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.299
H-Index - 35
eISSN - 1558-822X
pISSN - 1558-8211
DOI - 10.1007/s11899-020-00591-4
Subject(s) - blinatumomab , medicine , chimeric antigen receptor , antibody drug conjugate , oncology , immunotherapy , hematology , disease , cancer , immunology , intensive care medicine , leukemia , lymphoblastic leukemia , antibody , monoclonal antibody
Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy. Advances in multi-agent chemotherapy have resulted in dramatic improvements in the number of pediatric cases that result in a cure; however, until recently, treatment options for older adults or patients with relapsed and refractory disease were extremely limited. This review seeks to describe in greater detail a number of emerging novel treatment modalities recently approved for this cancer.